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Anti-angiogenic compound (TNP-470) inhibits mesangial cell prolifer-
ation in vitro and in vivo, Growth factors, especially basic fibroblast growth
factor (bFGF), platelet-derived growth factor (PDGF), and transforming
growth factor-n (TGF-j3) are known to play key roles in the pathogenesis
of mesangial proliferative glomerulonephritis. TNP-470 (AGM-1470), a
potent anti-angiogenic compound, has anti-growth factor properties and
inhibits the activation of cyclin-dependent kinase (cdk) 2 and phosphor-
ylation of RB protein. We investigated whether TNP-470 could suppress
growth factor induced mesangial cell proliferation in vitro and experimen-
tal model of mesangial proliferative glomerulonephritis in viva. TNP-470
inhibited potently PDGF- and bFGF-stimulated proliferation of rat
mesangial cells in vitro (IC50 = 50 pg/mI). In anti-Thy 1.1 glomerulone-
phritis, high dose use of TNP-470 (20 mg/kg/day) markedly suppressed
mesangial cell proliferation and mesangial matrix expansion on day 6;
however, mesangiolysis remained. Low dose use of TNP-470 (10 mg/kg/
day) moderately inhibited mesangial cell proliferation and mesangial
matrix synthesis, and induced appropriate glomerular healing on day 14 in
anti-Thy 1.1 glomerulonephritis. Thus, TNP-470 potently inhibits growth
factor-induced proliferation of mesangial cells in vitro, and mesangial cell
proliferation and extracellular matrix expansion in anti-Thy 1.1 glomeru-
lonephritis in viva. These results suggest a novel therapeutic potential of
TNP-470 in mesangial proliferative glomerulonephritis.
Mesangial cell proliferation as well as expansion of the mesan-
gial matrix are central features of various glomerular diseases [1,
2]. Anti-Thy 1.1 glomerulonephritis is a well-characterized model
in rats that is induced by the injection of an anti-thymocyte
antibody (anti-Thy 1.1), which leads to an acute phase of comple-
ment-dependent mesangial cell lysis followed by a phase of
intense mesangial cell proliferation and expansion of the mesan-
gial matrix, resembling the morphological features of human
mesangial proliferative glomerulonephritis [1, 3—8].
Growth factors, especially basic fibroblast growth factor
(bFGF) [6], platelet-derived growth factor (PDGF) [6, 7, 9], and
transforming growth factor-a (TGF-/3) [8, 9] are known to partic-
ipate in either the mesangial cell proliferation or the mesangial
matrix expansion that follows mesangial cell injury with anti-Thy
1.1 antibody. It has been demonstrated that the administration of
an antibody against PDGF inhibits mesangial cell proliferation,
and largely prevents the increased deposition of extracellular
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matrix in the anti-Thy 1.1 glomerulonephritis model [7]. This
suggests that PDGF has a central role in proliferative glomerular
disease. Therefore, it can be expected to use a compound, which
has anti-PDGF properties, as a promising agent for the therapy of
proliferative glomerular disease.
A potent anti-angiogenic compound of a synthetic analogue of
fumagillin, TNP-470 (AGM 1470), has been introduced recently
and has been demonstrated to suppress tumor growth [10, 11],
tumor metastasis [12] and collagen-induced arthritis [13] in vivo.
This compound inhibits potently the proliferation of endothelial
cells in the presence of bFGF as well as the other cell types, such
as smooth muscle cells in the presence of fetal bovine serum in
vitro [14, 15]. Inhibition of cdk2 activity and of phosphorylation of
RB protein is involved in the mechanisms of the anti-proliferative
action of TNP-470, and the target of TNP-470 may be located
relatively in the late G1 phase [16, 17]. Since in many ways
vascular smooth muscle cells resemble mesangial cells, we at-
tempted to investigate whether or not TNP-470 inhibits a prolif-
eration of rat mesangial cells stimulated by growth factors in vitro.
Furthermore, we investigated the effect of TNP-470 on mesangial
cell proliferation and extracellular matrix synthesis in anti-Thy 1.1
glomerulonephritis.
Methods
Cell culture
Rat mesangial cells were prepared from glomeruli isolated from
Sprague-Dawley rats by a sieving method as previously described
[18]. The cells at S to 8 passages were used for the following
experiments. Cultured cells were identified as mesangial cells by
morphological and by immunocytochemical staining as previously
described [19]. The cells were spindle-shaped in appearance, with
positive immunocytochemical staining for desmin, a-smooth mus-
cle actin and Thy 1.1 antigen, and negative staining for rat
endothelial cell antigen (OX-47) and von Willebrand factor.
Epithelial cell contamination was excluded by visual examination.
After confluency they were plated in 96-well tissue culture plates
(Costar Corp., Cambridge, MA, USA) at a density of 1 X io cells
per well. Then they were preincubated for 24 hours in serum-free
Dulbecco modified Eagle's medium (DME; Gibco BRL, Gaith-
ersburg, MD, USA). After 24 hours of preincubation, 20 nglml
bFGF (Biochemical Technologies Inc., Stoughton, MA, USA) or
PDGF-BB (Sigma Chemical Co., St. Louis, MO, USA) were
added into DME with various doses of TNP-470 dissolved in
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Fig. 1. Inhibition of mesangial cellproliferation by TNP-470 in Vitro. Values
are expressed as percentage of basal level, where basal level represents
mesangial cell number (as expressed optical density) cultured for 72 hours
in presence of DME alone. Data points represent means so of duplicate
determinations in 3 different experiments. < 0.01 as compared with the
control culture with 20 ng/ml growth factors (PDGF-BB or bFGF) in the
absence of TNP-470. Symbols are: (-•--) PDGF-BB 20 nglml; (_O—)
bFGF 20 ng/ml.
dimethylsuiphoxide (a final concentration of 0.1%) and cultured
for 72 hours.
Cell proliferation assay
Mesangial cell proliferation was measured by a colorimetric
assay utilizing the tetrazolium salt X1T (sodium 3'-[l-[(phe-
nylamino)-carbonyl]-3,4-tetrazolium]-bis(4-methoxy-6-nitro)-ben-
zene-sulfonic acid hydrate) as described [201. We found a linear
relationship between the absorbance at 450 nm and the number of
mesangial cells, which ranged from 1 X i03 to 3 X 104/mm3.
TGF-131 (R&D Systems, Inc., Minneapolis, MN, USA) -in-
duced increase of incorporation of 3[H]proline into TCA-precip-
itable proteins of mesangial cells was measured as previously
described [211.
High dose use of TNP-470 in anti-Thy 1.1 glomerulonephritis
Experimental protocol. Anti-rat thymocyte serum was produced
in New Zealand white rabbits by immunization with 1 X 10
Wistar rat thymocytes in complete Freund's adjuvant followed by
1 x 106 cells administered intravenously two and four weeks later.
Sera obtained one week after the last injection were heat inacti-
vated (56°C for 30 mm) and absorbed three times with packed
Wistar rat erythrocytes and three times with rat liver powder to
remove nonspecific reactivity [4]. Anti-Thy 1.1 glomerulonephritis
was induced in 140 to 170 g male Wistar rats (Charles River
Laboratories, Japan) by intravenous administration of 0.3 ml
anti-rat thymocyte serum per 100 g body weight. TNP-470 was
solubilized in a 5% ethanol and 5% arabic gum/saline mixture.
Four hours prior to a single injection of anti-thymocyte serum,
rats were administered TNP-470 (20 mg/kg, N = 6), or vehicle
Table 1. Comparison of total glomerular cellularity, mesangiolysis,
glomerular proliferating cells, glomerular monocyte/macrophages in
normal rats, control rats with anti-Thy 1.1 glomerulonephritis, and high
dose of TNP-470 (20 mg/kg/day) treated rats with anti-Thy-1.1
glomerulonephritis
Proliferating
Total
cells
Mesangiolysis
score
(PCNA+)
cells
Infiltrating
ED1+cells
Normal rats 58 5 0 0 0.6 0.1 1.6 0.2
Anti-Thy 1.1
glomerulonephritis,
day 2
Control 42 6 3.0 0 4.0 0.3 7.6 0.7
TNP-470 42 6 3.0 0 1.9 0.5° 6.8 0.5
Anti-Thy 1.1
glomerulonephritis,
day 4
Control 48 9 2.5 0.5 9.0 1.1 5.5 0.4
TNP-470 43 8 3.0 0 3.3 0.8° 6.3 0.6
Anti-Thy 1.1
glomerulonephritis,
day 6
Control 76 9 1.3 0.4 8.4 1.2 5.9 0.4
TNP-470 54 11° 2.4 0.5° 3.4 0.9° 6.9 0.4
Data are means SD, N = 6 each.
a P < 0.01 vs. control rats with anti-Thy 1.1 glomerulonephritis
(N = 6) subcutaneously. They received injections of TNP-470 or
vehicle on six successive days, starting with the anti-Thy 1.1 serum
injection. The effects of TNP-470 on the Thy-1.1 glomerulone-
phritis model were evaluated at three time points, which were the
day of initial proliferation (day 2), the day of peak proliferation
(day 4) and day 6, at which time both mesangial cell proliferation
and extracellular matrix expansion can be evaluated.
Histology. The following antibodies were used for indirect
immunoperoxidase staining of three .rm sections of methyl Car-
noy's fixed, paraffin-embedded tissue: PC 10 (Dako, Denmark), a
monoclonal antibody (mAb) to the proliferating cell nuclear
antigen (PCNA), which is a cell proliferation marker; ED-i
(Serotec, Kidllington, Oxford, UK), a mAb to rat monocytes and
macrophages; ASM-1 (Progen Biotechnik GmbH, Heidelberg,
Germany), a mAb against the a-smooth muscle isoform of actin;
PGF-007 (gift from Mochida Pharmaceutical, Tokyo, Japan), a
mAb to a human PDGF B-chain; CBL 181 (Cymbus Bioscience
Ltd., UK), a mAb to a human cellular (EDA) fibronectin.
MA-031-5 (Austral Biologicals, San Raman, CA, USA), a mAb to
rh-bFGF, was used for indirect immunoperoxidase staining of
acetone fixed, 3 j.m cryostat sections. TGF /31 (V) (Santa Cruz
Biotechnology, Inc., CA, USA), a rabbit polyclonal IgG to human
TGF-p1, was used for indirect immunoperoxidase staining of
paraformaldehyde fixed, 3 j.tm cryostat sections. Fluorescein
isothiocyanate (FITC)-conjugated goat IgG to rat C3 (Organon
Teknika Corp., Durham, NC, USA) was used for direct immuno-
fluorescence staining of ethanol fixed, 3 .tm cryostat sections.
Biopsied renal tissues for light microscopy were fixed in methyl
Carnoy's solution and embedded in paraffin. Three micrometer
sections were stained with the periodic acid/Schiff (PAS) reagent
and counterstained with hematoxylin. Quantitation of mesangial
proliferation and mesangiolysis was performed as previously
*
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Fig. 2. Histological changes in glomeruli. Compared with untreated control rats with anti-Thy 1.1 glomerulonephritis (A), high dose of TNP-470 treated
rats (B) had markedly less glomerular cellularity and a mesangial matrix on day 6. Mesangiolysis was persistent in glomeruli of high dose of TNP-470
treated rats (periodic acid/Schiff reagent with hematoxylin counterstain; X 460).
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Fig. 4. Glomendar immunostaining score for a-smooth muscle actin (A)
and EDA + fibronectin (B) in normal rats (), control rats () with
anti-Thy 1.1 giomerulonephritis (group A) and high dose of TNP-470 treated
rats (U) with anti-Thy 1.1 glomerulonephritis (group B). *p < 0.01 vs. group
A.
described [22]. For each biopsy, 30 glomeruli were examined
sequentially. The total number of nuclei per glomerular crosssec-
tion was calculated in PAS-stained sections. Mesangiolysis was
graded semi-quantitatively (0 to 4+) using the published scale
[22]. For the evaluation of the glomerular proliferating cells
(PCNA) and infiltrating monocytes/macrophages (ED1), im-
munoperoxidase staining was performed and the mean number of
each type of positive cell per biopsy was calculated. For the
evaluation of the immunoperoxidase stains for a-smooth muscle
actin, EDA fibronectin and bFGF, each glomerulus was graded
semiquantitatively based on the extent of mesangial staining, as 0
to 5% (grade 0); 5 to 25% (1+), 25 to 50% (2+), 50 to 75% (3+),
or > 75% (4+) of the glomerular tuft showing positive staining as
previously described [23]. For quantitation of the immunoperox-
idase stains for PDGF B-chain and TGF-pl in individual glomer-
uli, the semiquantitative scale reported by Yoshimura et al [24]
was used. For each biopsy, 20 glomeruli were evaluated and the
mean score per biopsy was calculated. For all biopsies, negative
controls consisted of substitution of the primary antibody with an
irrelevant murine monoclonal antibody.
For quantitation of glomerular mesangial matrix accumulation,
30 glomeruli were selected at random in PAS-stained sections.
The degree of mesangial matrix expansion was calculated as the
percentage of each glomerular tuft area occupied by mesangial
matrix as previously described [25] using software of image
analysis, Adobe Photoshop and NIH image.
Proteinuria. The rats were housed in metabolic cages on day 5
and 24-hour urinary protein excretion was measured by using the
biuret method.
Low dose use of TNP-470 in anti-Thy 1.1 glomerulonephritis
Anti-Thy 1.1 glomerulonephritis was induced in 150 to 160 g
male Wistar rats by intravenous administration of 0.3 ml anti-rat
thymocyte serum per 100 g body weight. Four hours prior to a
single injection of anti-thymocyte serum, rats were administered
TNP-470 (10 mg/kg, N = 5) or vehicle (N = 5) subcutaneously.
They received injections of TNP-470 or vehicle on 14 successive
days, starting with anti-thymocyte serum injection. The effects of
TNP-470 on the Thy-1.1 glomerulonephritis were evaluated on
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Fig. 5. Quantitation of glomerular mesangial matrix accumulation. Normal
rats were included for comparison. < 0.01, for high dose of TNP-470-
treated rats compared with control rats with anti-Thy 1.1 glomerulone-
phritis on day 6. Values are means SD.
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Fig. 3. Immunohistochemical staining of giomeruli for a-smooth muscle actin (A, B) and EDA + fibronectin (C, D) in control rats with anti-Thy 1.1
giomentlonephritis on day 6 (A, C), and in high dose of TNP-470 treated rats with anti-Thy 1.1 glomerulonephritis on day 6 (B, D) (immunoperoxidase stain
with methyl green counterstain. >< 330).
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Fig. 6. Immunohistochemical staining of glomeruli for bFGF (A, B), PDGF f3-chain (C, D) and TFG-131 (E, F) in control rats with anti-Thy 1.1
glomerulonephritis on day 6 (A, C, E), and in high dose of TNP-470 treated rats with anti-Thy 1.1 glomendonephritis on day 6 (B, D, F) (immunoperoxidase
stain with methyl green counterstain; X 330).
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Fig. 7. Effect of low dose use of TNP-470 on reconstmction of gIo'nendar tufts in anti-Thy 1.1 glomerulonephritis. On day 6, compared with control rats
with anti-Thy 1.1 glomerulonephritis (A), low dose of TNP-470 treated rats with anti-Thy 1.1 glomerulonephritis had less glomerular cellularity and
extracellular matrix deposition (B), but did not show extensive mesangiolysis as high dose of TNP-470 treated rats with anti-Thy 1.1 glomerulonephritis
(see Fig. 2B). On day 14, although moderate proliferative lesion still remained in control rats with anti-Thy 1.1 glomerulonephritis (C), glomerulus
showed advanced repopulation of capillaries and glomerular tuft architecture was restored to almost normal in low dose of TNP-470 treated group (D)
(periodic acid/Schifi' reagent with hematoxylin counterstain; X 460).
days 6 and 14. The following antibodies were used for immuno-
peroxidase staining of methyl Carnoy's fixed, paraffin-embedded
tissue: DAKO EPOS Anti-PCNA/HRP (Dako), a mAb to the
proliferating cell nuclear antigen, and horseradish peroxidase
coupled to an inert polymer backbone; and DAKO EPOS Anti-
Smooth Muscle Actin/HRP (Dako), a mAb to the a-smooth
muscle isoform of actin and horseradish peroxidase coupled to an
inert polymer backbone. The total number of nuclei per glomer-
ular crosssection, glomerular proliferating cells (PCNA), gb-
merular staining score of a-smooth muscle actin and mesangial
matrix index were evaluated as described above. Twenty-four-
hour urinary protein excretion was measured on days 5 and 13.
Statistics
Values are expressed as means SD. Comparison was by
Student's unpaired t-test or Dunnett-type test where it was
appropriate.
Results
TNP-470 inhibits potently mesangial cell proliferation in Vitro
bFGF and BB homodimer of human PDGF (PDGF-BB)
induced a dose-dependent increase of mesangial cell proliferation
compared to the control cultures after 72 hours. To examine the
inhibitory effect of TNP-470 on growth factor induced prolifera-
tion of mesangial cells, the cell culture medium was supplemented
with 20 ng/ml recombinant human bFGF or PDGF-BB. TNP-470
inhibited bFGF- or PDGF-BB-induced proliferation of mesangial
cells in a dose-dependent fashion and almost completely inhibited
at I ng/ml (2 nM) with an IC50 of approximately 50 pg/mI (0.1 nM)
(Fig. 1). Dimethylsulphoxide (a final concentration of 0.1%) alone
did not affect the mesangial cell proliferation (data not shown).
Viability of mesangial cells after incubation with these concentra-
tions was confirmed by the dye exclusion method using methylene
blue. No increase of lactate dehydrogenase into the culture
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Table 2. Comparison of glomerular b-FGF, PDGF B-chain and TGF-
/31 expression in normal rats, control rats with anti-Thy 1.1
glomerulonephritis and high dose of TNP-470 (20 mg/kg/day) treated
rats with anti-Thy 1.1 glomerulonephritis on day 6
PDGF
bFGF
staining
score
B-chain
staining
score
TGF-p1
staining
score
Normal rats 1.3 0.1 1.0 0.2 1.0 0.1
Anti-Thy 1.1 glomerulonephritis,
day 6
Control 2.5 0.3 2.0 0.4 2.2 0.3
TNP-470 1.1 0.3a 1.3 O.3 1.1 0.2
Data are means SD, N = 5 each.
a P < 0.01 vs. control rats with anti-Thy 1.1 glomerulonephritis
medium was noted. Seventy-two hours after the removal of
TNP-470, the cells showed normal growth. These results indicate
that the inhibition of mesangial cell proliferation is not due to
nonspecific toxicity. TNP-470 showed no inhibition on the TGF-
/31-induced increase of 3[H]proline incorporation into TCA-
precipitable proteins of mesangial cells (data not shown).
High dose of TNP-470 potently inhibits mesangial cell proliferation
and mesangial matrix expansion in anti- Thy 1.1 glomerulonephritis
Figure 2 shows a comparison of the microscopic appearance of
representative glomeruli on day 6. The mesangial hypercellularity
and extracellular matrix expansion were greatly reduced in the
TNP-470 treated group compared to the group receiving vehicle.
Control rats with untreated anti-Thy 1.1 glomerulonephritis
(group A) followed the typical disease course as previously
reported: total glomerular cell numbers decreased below normal
on day 2 after anti-Thy 1.1 serum injection, followed by a rapid
increase on day 4 to day 6. In contrast, although the total
glomerular cell numbers decreased below normal on day 2 in
TNP-470 treated rats (group B), the total glomerular cell number
on day 6 did not exceed the normal level, and the mesangiolysis
score remained high (Table 1). The number of proliferating
(PCNA) cells was markedly reduced in group B compared with
those in group A on days 2, 4 and 6 (a 53% reduction on day 2,
64% on day 4, and 60% on day 6; Table 1). Phenotypic change of
mesangial cell defined by a-smooth muscle actin expression in
mesangial regions [22] was also markedly reduced in group B on
days 2, 4 and 6 (Figs. 3 A, B and 4A). Glomerular staining of
fibronectin containing extra domain A (EDA fibronectin) was
also greatly reduced in group B on days 4 and 6 (Figs. 3 C, D and
4B). The mesangial matrix index was markedly reduced in group
B compared with that in group A on day 6 (Fig. 5). Increased
glomerular staining of bFGF, PDGF B-chain and TGF-/3 in group
A (Fig. 6 A, C, E) was significantly decreased on day 6 in group B
(Fig. 6 B, D, F and Table 2). Mesangial infiltration of monocytes/
macrophages (EDI positive cells) did not differ between the
groups on days 2 and 4, but rather were marginally increased in
group B on day 6. Since the majority of glomerular proliferating
cells (PCNA cells) in anti-Thy 1.1 glomerulonephritis have been
shown to be derived from mesangial cells [5], these results suggest
that the decrease of glomerular PCNA cells in group B is
considered to be mainly due to the decrease of proliferating
Table 3. Comparison of total glomerular cellularity, glomerular PCNA
positive cells, mesangial matrix index and glomerular expression of a-
smooth muscle actin in control rats with anti-Thy 1.1 glomerulonephritis
and low dose of TNP-470 (10 mg/kg/day) treated rats with anti-Thy 1.1
glomerulonephritis
Glomerular
staining
score of
Total Glomerular Mesangial a-smooth
glomerular PCNA+ matrix muscle
cells cells index actin
Anti-Thy 1.1
glomerulonephritis,
day 6
Control 79 10 9.0 1.0 50 12 2.6 0.2
TNP-470 63 6 5.6 1.2 28 6 1.3 0.3
Anti-Thy 1.1
glomerulonephritis,
day 14
Control 68 3 0.8 0.3 41 9 1.8 0.3
TNP-470 61 3 0.4 0.2a 23 3 1.1 0.2
Data are means SD, N = 5 each.
a P < 0.01 vs. control rats with anti-Thy 1.1 glomerulonephritis
mesangial cells. Intensity of immunofluorescence for rat comple-
ment C3 in the glomeruli of day 2 did not differ between the two
groups (data not shown).
When TNP-470 (20 mg/kg/day) was administered 48 hours after
Thy 1.1 antibody injection, inhibitory effects similar to those
described above were observed on day 6 (N = 6; total glomerular
cells; 52 12 vs. 76 9, mesangiolysis score; 2.3 0.6 vs. 1.3
0.4, PCNA cells; 4.3 0.7 vs. 8.4 1.2, EDA fibronectin
staining score; 1.4 0.1 vs. 2.5 0.4, mesangial matrix index;
23 5 vs. 52 7; P < 0.01 vs. control rats).
Twenty-four-hour urinary protein excretion was significantly
higher in the TNP-470 treated group than that in the control
group on day 5 (133 96 mg vs. 38 38 mg, P < 0.01 vs. control
rats).
Low dose of TNP-470 induces appropriate glomerular healing in
anti-Thy 1.1 glomerulonephritis
Compared to the high dose use of TNP-470 (20 mg/kg/day), the
low dose use of TNP-470 (10 mg/kg/day) showed a rather mild
inhibition of mesangial cell proliferation, phenotypic change of
mesangial cells and mesangial matrix expansion on day 6 in
anti-Thy 1.1 glomerulonephritis (Table 3 and Fig. 7B). On day 14,
although moderate proliferative lesions still remained in control
rats with anti-Thy 1.1 glomerulonephritis (Table 3 and Fig. 7C),
the glomerular tuft architecture was restored to almost normal in
low dose of TNP-470 treated rats with anti-Thy 1.1 glomerulone-
phritis (Fig. 7D).
Twenty-four-hour urinary protein excretion of the low dose
TNP-470 treated group was 45 20 mg on day 5, and 15 10 mg
on day 13, values not significantly different from those observed in
control group (40 30 mg on day 5, and 24 12 mg on day 13).
Discussion
In the present study, we showed that an anti-angiogenic com-
pound, TNP-470, inhibited almost completely PDGF- and bFGF-
stimulated proliferation of mesangial cells at a nanomolar con-
centration (2 nM, IC50 = 0.1 nM) in vitro. Several compounds have
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been reported to inhibit PDGF- or fetal calf serum-stimulated
proliferation of mesangial cells [26—30]; however, most of the
compounds need micromolar or more concentrations to inhibit
proliferation of mesangial cells. Although atrial natriuretic factor
has been reported to inhibit mesangial cell proliferation with 1 nM
concentration, the inhibitory effect is modest (—33%) [26]. TGF-13
has been known to prevent phosphoxylation of RB protein [31]
and inhibit almost completely PDGF- or bFGF-induced prolifer-
ation of mesangial cells at 1 ng/ml [321. Therefore, TNP-470
seems to have comparable potency to TGF-p and appears to be
the most potent synthetic compound that inhibits mesangial cell
proliferation reported so far.
Administration of a high dose of TNP-470, which inhibited
potently growth factor-induced proliferation of mesangial cells in
vitro, markedly suppressed mesangial cell proliferation, a pheno-
typic change of mesangial cells and mesangial matrix accumula-
tion on days 4 and 6 in rats with the anti-Thy 1.1 glomerulone-
phritis model in vivo. TNP-470, however, did not affect the
deposition of rat complement C3 and did not inhibit mesangiolysis
on day 2. Even without the initial 48 hours of therapy with
TNP-470, mesangial cell proliferation and extracellular matrix
accumulation were also similarly suppressed on day 6. Taken
together, TNP-470 is thought unlikely to influence the comple-
ment mediated mesangiolysis process; rather, it is thought to
inhibit potently mesangial cell proliferation and subsequent ex-
tracellular matrix expansion, which would be induced by growth
factors in an autocrine/paracrine fashion [1, 2]. When antibody to
PDGF was administered to rats with anti-Thy 1.1 glomerulone-
phritis, similar suppressive effects on mesangial cell proliferation
and mesangial matrix expansion have been reported, except that
PCNA cells were not decreased on day 2 [7]. The release of
bFGF following mesangial injury has been implicated as an
important mechanism in the initiation of mesangial cell prolifer-
ation [1, 5]. The decrease of PCNA cells on day 2 in TNP-470
treated rats can be explained by the inhibitory effect of TNP-470
on bFGF-induced proliferation of mesangial cells. The glomelular
expression of bFGF, PDGF B-chain and TGF-pl were decreased
in TNP-470 treated rats on day 6. Although we cannot exclude the
possibility that decreased expression of these growth factors may
be a secondary phenomenon due to the decreased mesangial cell
numbers, TNP-470 may directly inhibit the production of these
growth factors in mesangial cells.
Since mesangiolysis has been shown to correlate with protein-
uria in anti-Thy 1.1 glomerulonephritis [3], the higher urinary
protein excretion in the high dose (20 mg/kg/day) TNP-470
treated group may reflect the higher incidence of mesangiolysis
that remained without mesangial cell proliferation. However,
when half of a dose (10 mg/kg/day) of TNP-470 was administered
for 2 weeks, the glomerular tuft architecture was restored to
almost normal on day 14 and no significant increase of urinary
protein excretion was found compared to the control group. For
the reconstruction of glomerular capillaries after mesangiolysis,
especially in the microaneutysms, adequate proliferation and
migration of endothelial cells are thought to be needed [33]. Since
it has been reported that TNP-470 does not affect the migration of
endothelial cells in vitro [34], a well controlled reparation process
could be accomplished by using this potent anti-proliferative
compound in an appropriate dose.
TGF-p plays key roles in the accumulation of pathological
extracellular matrix in glomerulonephritis [8, 9, 35]. Mesangial
matrix expansion and glomerular staining for TGF-131 was mark-
edly reduced in TNP-470 treated rats on day 6. Since TNP-470 did
not inhibit a TGF-f31 induced increase of proline incorporation
into mesangial cells in vitro, the inhibitory effect of TNP-470 on
extracellular matrix expansion in Thy 1.1 glomerulonephritis is
not thought to be a direct effect of TNP-470 on TGF-f31; rather,
it may reflect the inhibition of mesangial cell production of
TGF-J31 secondary to the inhibitory effect on PDGF [36, 37].
Moreover, since RB protein regulates TGF-131 promoter activity
through RB control element (RCE) [38], there is another possi-
bility that TNP-470 may suppress mesangial cell production of
TGF-pl by inhibiting phosphorylation of RB protein [16]. Isaka et
al, in contrast to our speculation, did not find PDGF-induced
extracellular matrix expansion in their in vivo gene transfer
experiment [9]. Further studies are needed to clarify the mecha-
nisms of suppressive effect of TNP-470 on these points in vivo.
Attempts to treat anti-Thy 1.1 mesangial proliferative glomer-
ulonephritis using antibodies against growth factors [7, 8],
decorin, a TGF-f3 inhibitor [39], heparin [401 and interferon-y [41]
have been reported and substantial suppressive effects have been
described. TNP-470 showed a conspicuous suppressive effect on
mesangial cell proliferation and extracellular matrix expansion in
the anti-Thy 1.1 glomerulonephritis. Since TNP-470 has already
been used safely in clinical trials on malignant tumor therapy [42],
the compound could be used as a promising agent for the
treatment of mesangial proliferative glomerulonephritis in hu-
mans.
In conclusion, the current study demonstrates a conspicuous
suppressive effect of TNP-470, a potent anti-angiogenic com-
pound, which potently inhibits growth factor-induced prolifera-
tion of mesangial cells in vitro, and mesangial cell proliferation
and extracellular matrix expansion in anti-Thy 1.1 glomerulone-
phritis model in vivo. This is the first study to investigate the effect
of anti-angiogenic compound on experimental mesangial prolif-
erative glomerulonephritis, and suggests a novel therapeutic
potential in mesangial proliferative glomerular disease.
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